Food Challenge at Home or in Medical Practice - the FoodCHOMP Study

Not Applicable

Recruiting

• Conditions: Food Allergies

• Registration Number: NCT06916819
• Lead Sponsor: Austin Health

Brief Summary

This is a pilot, multi-centre, randomised clinical trial evaluating the safety and feasibility of a home-based oral food challenge in adults with low-risk food allergy labels. Eligible participants are aged 18 years or older and have a self-reported food allergy with negative skin prick testing to the implicated food. Participants will be randomised to either a home-based or standard in-clinic food challenge. The primary aim is to determine the safety of home challenges, measured by the rate of immune-mediated adverse events. Secondary aims include feasibility of recruitment and delivery, protocol adherence, quality of life, and food reintroduction outcomes.

Detailed Description

Food allergies are highly prevalent and contribute to significant patient anxiety and healthcare utilisation. Many individuals carry food allergy labels without confirmation through diagnostic food challenge, resulting in unnecessary food avoidance. In-clinic food challenges are the current standard for confirming tolerance but are resource-intensive and often delayed. This study evaluates whether selected low-risk adults can safely complete a structured oral food challenge at home.

This is a pilot, multi-centre, randomised controlled trial conducted at two tertiary allergy centres in Victoria, Australia (Austin Health and Royal Melbourne Hospital). Adults referred with a reported food allergy will undergo clinical assessment and skin prick testing. Those with negative skin testing (\<3mm wheal) to the implicated food and meeting other eligibility criteria will be randomised 1:1 to either:

* Intervention: Home-based oral food challenge over five days, beginning with a single supervised dose in-clinic and followed by four incremental doses at home with daily clinical follow-up.

* Control: Standard in-clinic oral food challenge using a protocol derived from PRACTALL and ASCIA guidelines.

The primary outcome is the proportion of participants experiencing an immune-mediated adverse event during food challenge. Secondary outcomes include feasibility metrics (eligibility, recruitment, delivery), non-immune mediated adverse events, protocol adherence, quality of life (measured by FAQLQ-12), time to challenge, and real-world food reintroduction.

The study will enrol 120 participants (60 per arm). Outcomes will inform the design of a future non-inferiority trial and may support integration of home challenges into routine practice for selected patients.

Study Timeline

• Study First Submitted: 2025-03-26
• Status Verified: 2025-04
• Study First Submitted QC: 2025-04-01
• Study First Posted: 2025-04-08
• Last Update Submitted: 2025-04-15
• Study Start: 2025-04-16
• Last Update Posted: 2025-04-17
• Primary Completion: 2026-07-01
• Study Completion: 2026-12-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

1. Negative (<3mm) fresh or extract skin testing to the food implicated within their allergy label
2. Aged greater than 18 years

Exclusion Criteria

• Evidence of prior sensitisation to challenge food 0 Defined as previously positive skin testing or allergen specific IgEs if available
• Pregnancy
• Patients with poorly controlled asthma - defined as an ACQ5 scores >1 at the time of enrolment
• Patients with a history of food reactions that is not-consistent with an IgE mediated process; i.e. exclusively gastrointestinal symptoms, FPIES
• Patients with a clear history of food-dependent exercise induced anaphylaxis
• Patients on a concurrent medication which may influence the outcome of the challenge;
• Antihistamine therapy; Patients receiving more than stress dose steroids (i.e. > 50mg QID hydrocortisone [or steroid equivalent]); Omalizumab
• Any other illness that, in the investigator's judgement, will substantially increase the risk associated with subject's participation in this study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Proportion of participants experiencing immune-mediated adverse events during food challenge	During the food challenge period (Days 1-5 post-randomisation)	Immune-mediated adverse events are defined as clinical symptoms consistent with IgE-mediated food allergy occurring during the food challenge, including but not limited to: urticaria, angioedema, vomiting, diarrhoea, or respiratory compromise (e.g., wheezing, cough, stridor). Events will be recorded according to a standardised adverse event form. For home challenges, participants will self-report symptoms daily and receive follow-up via nursing staff. In-clinic events will be recorded by supervising clinicians.

Secondary Outcome Measures

Name	Time	Method
Proportion of screened patients who are eligible for randomisation (Eligibility-to-screened ratio)	Baseline visit	Feasibility metric defined as the proportion of patients referred to outpatient allergy clinic who meet the trial eligibility criteria (including negative skin prick testing to the implicated food and absence of exclusion criteria).
Proportion of eligible patients who consent to participate (Recruitment-to-eligibility ratio)	At consent discussion (baseline visit)	Feasibility of recruitment measured as the proportion of eligible patients who provide written informed consent to participate in the trial.
Proportion of randomised participants who receive the allocated intervention (Intervention-to-recruitment ratio)	Day 1 to Day 5 (intervention delivery period)	Defined as the proportion of randomised participants who complete their allocated food challenge (home or in-clinic) in accordance with protocol.
Difference in proportion of participants tolerant to challenge food	At completion of challenge (Day 5)	Defined as the proportion of participants in each arm who successfully consume the full challenge dose without meeting stopping criteria or experiencing adverse events. Tolerance is determined according to protocol-defined thresholds.
Time from clinic referral to challenge completion	From the date of referral for food challenge to date of challenge completion or withdrawal from the study assessed up to 60 months.	Measured in days to assess whether home-based challenge reduces diagnostic delay compared to in-clinic challenge.; Data collected through clinic administrative records.
Proportion of participants experiencing non-immune mediated adverse events	Day 1 to Day 5 (challenge period)	Non-immune mediated events include those not consistent with IgE-mediated allergy and not meeting serious adverse event criteria. Examples: taste aversion, food refusal, procedural anxiety. Events will be recorded via self-report or in-clinic observation.
Proportion of participants with severe adverse reactions (anaphylaxis or death)	Day 1 to Day 5 (challenge period)	Serious adverse events are defined per ICH-GCP and include anaphylaxis (as per ASCIA criteria) or death.
Change in Food Allergy Quality of Life (FAQLQ-12) score from baseline	Baseline and 6 months post-randomisation	Measured using the FAQLQ-12, a validated 12-item quality of life tool for adults with food allergy. Change in score will be assessed as a continuous variable.
Proportion of participants consuming the challenge food post-trial	At 6-month follow-up	Defined as the proportion of participants who report active inclusion of the challenge food in their diet at least once per week following a successful challenge.

Trial Locations

Locations (2)

Austin Health; 🇦🇺 Melbourne, Victoria, Australia

Royal Melbourne Hospital; 🇦🇺 Melbourne, Victoria, Australia